Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update

25Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) is a rare primary liver cancer that is composed of both hepatocellular and cholangiocellular differentiated cells. It is slightly more common in men and among Asian and Pacific islanders. Overall, risk factors are similar to classic risk factors of hepatocellular carcinoma (HCC). The classification has significantly evolved over time. The last WHO classification (2019) mainly emphasized diagnosis on morphological basis with routine stainings, discarded previously recognized classifications with carcinomas with stem cell features, introduced intermediate cell carcinoma as a specific subtype and considered cholangiolocarcinoma as a subtype of cholangiocellular carcinoma. Immunohistochemical markers may be applied for further specification but have limited value for diagnosis. Recent discoveries in molecular pathway regulation may pioneer new therapeutic approaches for this poor prognostic and challenging diagnosis.

Cite

CITATION STYLE

APA

Roßner, F., Sinn, B. V., & Horst, D. (2023, January 1). Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update. Cancers. MDPI. https://doi.org/10.3390/cancers15020494

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free